Bright Minds Biosciences recently announced significant progress with BMB-101 as a potentially effective treatment for Dravet Syndrome. Because this rare form of epilepsy is not well understood, our Chief Medical Officer, Dr. Revati Shreeniwas, MD, FCCP, prepared this background. Dravet Syndrome is a rare form of severe pharmacoresistant epilepsy with onset in early childhood.…
Vancouver, BC – December 6, 2021 – Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (Nasdaq: DRUG) (CSE: DRUG), a biotechnology company focused on developing novel drugs for the targeted treatment of neuropsychiatric disorders, epilepsy, and pain, today announced that Ian McDonald, Chief Executive Officer, will present virtually at the Stifel GMP 2nd Annual…
With the COVID-19 pandemic upending life in every corner of the world and putting unwelcome pressure on people vulnerable to depression, suicide and addiction, there has never been a better time to consider new treatments for mental health challenges. One field gaining particularly rapid traction is psychedelics. Of course, substances such as LSD and…
— Hundreds of de novo patentable psychedelic-based compounds created through discovery program— — Company plans to announce lead molecule in first quarter of 2022 — Vancouver, BC – November 30, 2021 – Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (Nasdaq: DRUG) (CSE: DRUG), a biotechnology company focused on developing novel drugs for…
Effective today—Bright Minds Biosciences shares will commence trading on Nasdaq under the ticker symbol “DRUG.” Bright Minds is already listed on the Canadian Stock Exchange (CSE:DRUG) under the same symbol. Nasdaq Stock Market LLC approved the listing of the company’s common stock on The Nasdaq Capital Market. Bright Minds’ team of drug designers developed psychedelics…
Vancouver, BC – November 3, 2021 – Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (Nasdaq: DRUG) (CSE: DRUG), a biotechnology company focused on developing novel drugs for targeted treatment of neuropsychiatric disorders, epilepsy and pain, today announced that The Nasdaq Stock Market LLC has approved the listing of the Company’s common stock on…
Vancouver, BC – October 7, 2021 – Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (CSE: DRUG) (OTCQB: BMBIF), a biotechnology company focused on developing novel drugs for targeted treatment of neuropsychiatric disorders, epilepsy and pain, today announced that Ian McDonald, Chief Executive Officer of Bright Minds, will present at the LD Micro Main…
Lead program, BMB-101, advances to IND-enabling toxicology studies with the aim of commencing human trials in 1H 2022 VANCOUVER, British Columbia, Sept. 22, 2021 (GLOBE NEWSWIRE) — Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (CSE: DRUG) (OTCQB: BMBIF), a biotechnology company focused on developing novel drugs for targeted treatment of neuropsychiatric disorders,…
Vancouver, BC – September 8, 2021 – Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (CSE: DRUG) (OTCQB: BMBIF), a biotechnology company focused on developing novel drugs for targeted treatment of neuropsychiatric disorders, epilepsy and pain, today announced that Ian McDonald, Chief Executive Officer, and Dr. Alan Kozikowski PhD, Chief Scientific Officer, will be…
Psychedelics have become an area of increasing investment and drug development activities as an emerging group of companies is working to develop these compounds as treatments for neurologic and psychiatric conditions. That’s because of the ability of these drugs to target serotonin, which plays a critical role in the regulation of cognitive function, emotions, memory,…
×
"*" indicates required fields